おかえりなさい
Click “ログイン” to agree to Cointime’s 利用規約 and acknowledge that Cointime’s プライバシーポリシー applies to you.
アカウント登録
Already have an account?
Click “page.Sign up” to agree to Cointime’s <a class="underline" href="#term-of-service">利用規約</a> and acknowledge that Cointime’s a class="underline" href="#privacy-policy">プライバシーポリシー</a> applies to you.
siteでログインする
siteで登録する
あなたのメールアドレス
受信トレイを確認する
Click the link we sent to to sign in.
Click the link we sent to to sign up.
TransPharma Medical
company
About
TransPharma Medical is a specialty pharmaceutical company focused on the development and commercialization of drug-products.
Highlights
Details
- Last Funding Type
- Series C
- Last Funding Money Raised
- $18M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2000
- Operating Status
- Active
TransPharma Medical Ltd. is a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an innovative active transdermal drug delivery technology. Their current proprietary drug-product development programs include ViaDerm-hPTH (1-34), a transdermal hPTH (1-34) product to treat osteoporosis, undergoing Phase 2B clinical trials, which is developed in collaboration with Eli Lilly, and two additional peptides currently in Phase 1.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$18M
TransPharma Medical has raised a total of
$18M
in funding over 2 rounds. Their latest funding was raised on
Jul 24, 2006 from a Series C round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 24, 2006 | Series C | $18M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
TransPharma Medical is funded by 2 investors.
TIF Ventures Pte
and T2C2 Capital
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series C |
T2C2 Capital
|
— | Series C |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
